

해외 바이오의약품 임상 현황 (2020.05.25~2020.05.31)

한국바이오의약품협회, 2020.6.2.
출처: ClinicalTrials.gov

○ 미국 26건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04379518	Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients	Malignant Neoplasm SARS Coronavirus 2 Infection	Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04404088	Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma	Ann Arbor Stage III Grade 1 Follicular Lymphoma Ann Arbor Stage III Grade 2 Follicular Lymphoma Ann Arbor Stage III Grade 3 Follicular Lymphoma Ann Arbor Stage IV Grade 1 Follicular Lymphoma Ann Arbor Stage IV Grade 2 Follicular Lymphoma Ann Arbor Stage IV Grade 3 Follicular Lymphoma Grade 3a Follicular Lymphoma	Drug: Acalabrutinib Drug: Lenalidomide Biological: Rituximab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04361552	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Chronic Renal Failure Coronary Artery Disease Diabetes Mellitus Malignant Neoplasm SARS Coronavirus 2 Infection	Other: Best Practice Biological: Tocilizumab	Emory University National Cancer Institute (NCI)	Phase 3
NCT04359784	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleucel	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi	Phase 2
NCT04336943	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	Biochemically Recurrent Prostate Carcinoma Prostate Adenocarcinoma	Biological: Durvalumab Drug: Olaparib Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2
NCT04329065	Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2
NCT04318678	CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)	Acute Myeloid Leukemia	Drug: CD123-CAR T Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Drug: Rituximab	St. Jude Children's Research Hospital	Phase 1
NCT04267120	Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)	Renal Cell Carcinoma	Drug: Lenvatinib Drug: Pembrolizumab Procedure: Research blood collection	Washington University School of Medicine Merck Sharp & Dohme Corp.	Phase 2
NCT04230304	Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study	Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Lymphocytic Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Small Lymphocytic Lymphoma	Biological: Daratumumab Drug: Ibrutinib	Mayo Clinic National Cancer Institute (NCI)	Phase 2
NCT04189952	Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Diffuse Large B Cell Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Leukemia Marginal Zone Lymphoma	Drug: Acalabrutinib Drug: Rituximab Drug: Ifosfamide Drug: Carboplatin Drug: Etoposide	University of Miami AstraZeneca	Phase 2
NCT04169711	Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma	Clear Cell Renal Cell Carcinoma	Drug: ARO-HIF2	Arrowhead Pharmaceuticals	Phase 1
NCT04150562	Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma	Clear-Cell Renal Carcinoma	Drug: rhIL-15 Biological: Avelumab	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2
NCT04128176	Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid	Bullous Pemphigoid	Drug: Rituximab combined with Omalizumab	University of California, Davis	Phase 3
NCT04119830	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer	Metastatic Colorectal Adenocarcinoma Microsatellite Stable Mismatch Repair Proficient Refractory Colorectal Adenocarcinoma Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IVD Colorectal Cancer AJCC v8 Stage IVE Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Unresectable Colorectal Carcinoma	Biological: Pembrolizumab Other: Questionnaire Administration Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI) AIM BioPharma	Phase 2
NCT03993327	An Imaging Agent (I-124 MSA) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer	Colorectal Carcinoma Metastatic in the Liver Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Iodine I 124 Monoclonal Antibody MSA Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1

해외 바이오의약품 임상 현황 (2020.05.25~2020.05.31)

한국바이오의약품협회, 2020.6.2.
출처: ClinicalTrials.gov

NCT03982004	Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer	Metastatic Breast Cancer	Device: Epicutaneous cryoimmunotherapy Drug: Topical imiquimod Drug: Pembrolizumab Other: Dermatologic Quality of Life Index Other: Functional Assessment of Cancer Therapy Drug: Intra-lesional GM-CSF Device: Cry-AC Procedure: Cutaneous tumor biopsy Procedure: Peripheral blood draw for research	Washington University School of Medicine Merck Sharp & Dohme Corp.	Phase 1
NCT04254107	A Safety Study of SGN-TGT in Patients With Advanced Cancer	Non-small Cell Lung Cancer Gastric Carcinoma Classical Hodgkin Lymphoma Diffuse Large B-cell Lymphoma Peripheral T-cell Lymphoma	Drug: SGN-TGT Drug: pembrolizumab	Seattle Genetics, Inc.	Phase 1
NCT04402060	A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19	COVID Covid-19 Coronavirus Coronavirus Infection Severe Acute Respiratory Syndrome Severe Acute Respiratory Syndrome Coronavirus 2 Sars-CoV2 Ards Acute Respiratory Distress Syndrome	Drug: APL-9 Other: Vehicle Control	Apellis Pharmaceuticals, Inc.	Phase 1 Phase 2
NCT04349267	Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors	Advanced Solid Tumor	Biological: BMS-986315 Biological: nivolumab Biological: cetuximab	Bristol-Myers Squibb	Phase 1 Phase 2
NCT04405076	Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older	SARS-CoV-2	Biological: Biological: mRNA-1273: 50 mcg Other: Placebo Biological: Biological: mRNA-1273: 100 mcg	ModernaTX, Inc. Biomedical Advanced Research and Development Authority	Phase 2
NCT04351230	Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 HER2 Positive Breast Carcinoma Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	Drug: Abemaciclib Biological: Trastuzumab Emtansine	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2
NCT04285567	A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax Drug: Fludarabine Drug: Cyclophosphamide Drug: Rituximab Drug: Bendamustine	Hoffmann-La Roche	Phase 3
NCT04232553	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	Phase 3
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (Pvd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2
NCT04379596	Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)	Gastric Cancer	Drug: Fluorouracil (5-FU) Drug: Capecitabine Biological: Durvalumab Drug: Oxaliplatin Biological: Trastuzumab Drug: Trastuzumab deruxtecan Drug: Cisplatin	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Phase 1 Phase 2

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (Pvd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3

해외 바이오의약품 임상 현황 (2020.05.25~2020.05.31)

한국바이오의약품협회, 2020.6.2.
출처: ClinicalTrials.gov

○ 프랑스 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04394286	A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects	Hemophilia B	Genetic: SHP648	Baxalta now part of Shire Shire	Phase 1 Phase 2
NCT03548428	Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)	Sarcoma Radiosurgery	Drug: Atezolizumab Radiation: SBRT	Centre Antoine Lacassagne Centre Hospitalier Universitaire de Caen Roche Pharma AG	Phase 2
NCT04285567	A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax Drug: Fludarabine Drug: Cyclophosphamide Drug: Rituximab Drug: Bendamustine	Hoffmann-La Roche	Phase 3
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2

○ 독일 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04340193	A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Liver Cancer	Biological: nivolumab Biological: ipilimumab	Bristol-Myers Squibb	Phase 3
NCT04379596	Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)	Gastric Cancer	Drug: Fluorouracil (5-FU) Drug: Capecitabine Biological: Durvalumab Drug: Oxaliplatin Biological: Trastuzumab Drug: Trastuzumab deruxtecan Drug: Cisplatin	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Phase 1 Phase 2
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3
NCT04232553	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	Phase 3
NCT04394286	A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects	Hemophilia B	Genetic: SHP648	Baxalta now part of Shire Shire	Phase 1 Phase 2

○ 중국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04397926	Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer	Non Small Cell Lung Cancer	Drug: Individualized neoantigen peptides vaccine	Sun Yat-sen University Tianjin Hengjia Biotechnology Development co., LTD	Phase 1
NCT04340401	Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen	Rectal Cancer	Drug: SHR-1210 Drug: Oxaliplatin Drug: Capecitabine Radiation: Intensity modulated radiotherapy Procedure: Total mesorectal excision	Beijing Cancer Hospital	Phase 2
NCT04326296	The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer	Colorectal Neoplasms	Drug: PD-L1 Monoclonal Antibody Combined With Lenalidomide	LiNing Henan Cancer Hospital	Phase 1
NCT04325698	A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC	Advanced Non-squamous NSCLC	Drug: PF-06439535 (CN) Drug: Bevacizumab-EU Drug: Paclitaxel Drug: Carboplatin	Pfizer	Phase 3
NCT04321330	A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma	Carcinoma, Thymic	Drug: Atezolizumab	Hoffmann-La Roche	Phase 2
NCT04308785	Atezolizumab Consolidation in Limited Stage Small Cell Lung Cancer	Carcinoma, Small Cell Lung	Drug: Atezolizumab Drug: Cisplatin Drug: Carboplatin Drug: Etoposide	Hoffmann-La Roche	Phase 2

해외 바이오의약품 임상 현황 (2020.05.25~2020.05.31)

한국바이오의약품협회, 2020.6.2.
출처: ClinicalTrials.gov

○ 일본 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04240704	Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)	Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia	Drug: JBH492	Novartis Pharmaceuticals Novartis	Phase 1
NCT04317066	A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)	Lymphoma, B-Cell	Drug: Pembrolizumab	Merck Sharp & Dohme Corp.	Phase 1
NCT04397263	A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease	Crohns Disease	Drug: Guselkumab	Janssen Pharmaceutical K.K.	Phase 3
NCT04232553	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	Phase 3
NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Multiple Myeloma	Drug: JNJ-68284528 Drug: Pomalidomide Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab	Janssen Research & Development, LLC	Phase 3